Today: 19 June 2026
Goldman Sachs stock edges higher before CPI and a packed week of bank earnings
10 January 2026
1 min read

Goldman Sachs stock edges higher before CPI and a packed week of bank earnings

NEW YORK, January 9, 2026, 20:00 EST — Market closed.

Shares of The Goldman Sachs Group Inc (GS) closed Friday up roughly 0.4%, finishing at $938.98, gaining $4.15 from Thursday’s close. The stock fluctuated between $932.84 and $946.14 during the session, with around 1.1 million shares changing hands.

Goldman now faces a hectic period as major U.S. banks prepare to kick off fourth-quarter earnings. Investors will be watching closely for early signals on the economy and deal activity. “The banks are going to be telling you something that is going to be pretty important because they’re on the front lines,” said Jack Janasiewicz, portfolio manager at Natixis Investment Managers Solutions.

Tuesday delivers December’s consumer price index, a crucial inflation gauge that could shift forecasts for Federal Reserve rate cuts. The Fed is set to meet next on Jan. 27-28.

U.S. stocks wrapped up the week strong, with the S&P 500 hitting a new peak at 6,966.28, up 0.65%. December’s jobs report revealed hiring slowed more than anticipated, even as unemployment slipped to 4.4%. One strategist noted investors are “getting granular” in their stock selections.

In deal news, Bloomberg reports CK Hutchison has tapped Goldman and UBS to lead a planned IPO for A.S. Watson, aiming to raise $2 billion or more. The listing is expected to be dual, covering both Hong Kong and London. This move adds another item for investors tracking whether equity issuance is truly picking up.

Goldman closes the week roughly 2.4% shy of its 52-week peak at $961.69, while the 52-week trough stands at $439.38. Analysts note resistance near $945.85 and support around $932.41—essentially zones where selling or buying pressure tends to kick in.

Goldman plans to release its fourth-quarter earnings around 7:30 a.m. ET on Jan. 15, with a conference call set for 9:30 a.m. Traders will focus on market trading results, any rise in investment-banking fees, and cost trends as the firm heads into 2026.

But the path ahead is far from certain. A stronger inflation report or new tariff concerns could shake up rate forecasts and weaken demand for bank shares, despite any renewed buzz about deals.

Up next: the December 2025 CPI data, due out at 8:30 a.m. ET on Jan. 13. JPMorgan is set to release earnings before the open that day, with Bank of America following on Jan. 14. Morgan Stanley and Goldman Sachs will report on Jan. 15.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • SpaceX Surges Post-IPO to Nearly $2.64 Trillion Valuation with Cursor Acquisition
    June 18, 2026, 10:42 PM EDT. SpaceX SPCX stock soared to $201.68, up 5% on Tuesday, marking a 50% gain above its $135 IPO price. The $60 billion acquisition of AI coding platform Cursor fueled investor enthusiasm, pushing SpaceX's market value to about $2.64 trillion, making it the sixth-largest U.S. public company. Despite the massive valuation, SpaceX's 2025 revenue is forecast at $18.7 billion, projected to reach $36.8 billion in 2026, far below other mega-caps. The company's price-to-sales ratio rests near 141 on 2025 revenue, indicating sky-high valuation multiples. Morningstar's analyst Nicolas Owens estimates SpaceX's fair value at $62 per share, noting the premium partly stems from technology bets like Starlink and Starship rockets development.

Latest articles

Kardigan pops in first Nasdaq trading after $400 million IPO

Kardigan pops in first Nasdaq trading after $400 million IPO

19 June 2026
Kardigan surged 37.5% above its $16 IPO price to close at $22 after raising $400 million in an upsized Nasdaq debut, signaling renewed investor appetite for large biotech IPOs as the company advances three late-stage cardiovascular drug candidates.
Kohl’s stock slides 5% as tariff ruling delay hits retailers; KSS traders eye Jan. 14
Previous Story

Kohl’s stock slides 5% as tariff ruling delay hits retailers; KSS traders eye Jan. 14

Lululemon stock drops nearly 4% as tariff ruling stays unresolved — what to watch next
Next Story

Lululemon stock drops nearly 4% as tariff ruling stays unresolved — what to watch next

Go toTop